Nutanix announced the addition of Eric K. Brandt to its board of directors, effective May 15, 2025. Brandt brings extensive expertise in CEO and CFO roles across various industries, along with over 30 years of global experience in finance, operations, and corporate governance. He previously served as Chief Financial Officer of Broadcom Corporation from 2007 until its acquisition by Avago Technologies Limited in 2016, playing a pivotal role in its growth into a leading semiconductor firm.
Brandt also held senior executive positions, including President and CEO of Avanir Pharmaceuticals, Inc. and Chief Financial Officer of Allergan, Inc. He currently serves on the boards of Gen Digital Inc., Lam Research Corporation, The Macerich Company, and Option Care Health, Inc., and previously served on the boards of Altaba Inc. and DENTSPLY SIRONA Inc. Brandt holds a B.S. in Chemical Engineering from the Massachusetts Institute of Technology and an M.B.A. from Harvard Business School. Additionally, David Humphrey resigned from Nutanix?s board of directors, effective May 15, 2025. Humphrey, a Partner at Bain Capital, joined the Nutanix Board as part of Bain Capital?s $750 million investment in September 2020.
Following Humphrey?s resignation, Max de Groen, another Partner at Bain Capital, will continue to serve as a member of Nutanix?s board of directors.
